Skip to main content
Top
Published in: Clinical and Experimental Nephrology 2/2010

01-04-2010 | Case Report

Torsades de Pointes induced by a combination of garenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice

Authors: Kanyu Miyamoto, Hirohisa Kawai, Ryuhei Aoyama, Hitoshi Watanabe, Keisuke Suzuki, Norihiro Suga, Wataru Kitagawa, Naoto Miura, Kazuhiro Nishikawa, Hirokazu Imai

Published in: Clinical and Experimental Nephrology | Issue 2/2010

Login to get access

Abstract

We report an 82-year-old man who developed ventricular tachycardia and Torsades de Pointes (TdP) after oral administration of garenoxacin, a novel quinolone antibiotic agent that differs from the third-generation quinolones, for pneumonia. He had hypokalemia (K 2.3 mmol/L) induced by licorice and also had received disopyramide for arrhythmia, bicalutamide for prostate cancer, and silodosin for prostate hypertrophy. After taking him off all drugs and administering spironolactone supplemented with potassium, his low serum potassium level was ameliorated. Therefore, although garenoxacin reportedly causes fewer adverse reactions for cardiac rhythms than third-generation quinolone antibiotics, one must be cautious of the interference of other drugs during hypokalemia in order to prevent TdP.
Literature
1.
go back to reference Rodent DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013–22.CrossRef Rodent DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013–22.CrossRef
2.
go back to reference Akita M, Shibazaki Y, Izumi M, Hiratsuka K, Sakai T, Kurosawa T, et al. Comparative assessment of prulifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia. J Toxicol Sci. 2004;29:63–71.CrossRefPubMed Akita M, Shibazaki Y, Izumi M, Hiratsuka K, Sakai T, Kurosawa T, et al. Comparative assessment of prulifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia. J Toxicol Sci. 2004;29:63–71.CrossRefPubMed
3.
go back to reference Hayashi Y, Ikeda U, Hashimoto T, Watanabe T, Mitsuhashi T, Shimada K. Torsades de Pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. PACE. 1999;22:672–4.PubMed Hayashi Y, Ikeda U, Hashimoto T, Watanabe T, Mitsuhashi T, Shimada K. Torsades de Pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. PACE. 1999;22:672–4.PubMed
4.
go back to reference Walker BR, Edwards CR. Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess. Endocrinol Metabol Clin North Am. 1994;23:359–77. Walker BR, Edwards CR. Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess. Endocrinol Metabol Clin North Am. 1994;23:359–77.
5.
go back to reference Kato H, Kanaoka M, Yano S, Kobayashi M. 3-Monoglucuronyl-glycyrrhetinic acid is a major metabolite that causes licorice-induced pseudoaldosteronism. J Clin Endocrinol Metab. 1995;80:1929–33.CrossRefPubMed Kato H, Kanaoka M, Yano S, Kobayashi M. 3-Monoglucuronyl-glycyrrhetinic acid is a major metabolite that causes licorice-induced pseudoaldosteronism. J Clin Endocrinol Metab. 1995;80:1929–33.CrossRefPubMed
6.
go back to reference Homma M, Ishihara M, Qian W, Kohda Y. Effects of long term administration of Shakuyaku-kanzo-To and Shosaiko-To on serum potassium levels. Yakugaku Zasshi. 2006;126:973–8. (Japanese, English abstract).CrossRefPubMed Homma M, Ishihara M, Qian W, Kohda Y. Effects of long term administration of Shakuyaku-kanzo-To and Shosaiko-To on serum potassium levels. Yakugaku Zasshi. 2006;126:973–8. (Japanese, English abstract).CrossRefPubMed
7.
go back to reference Eriksson JW, Carlberg B, Hillorn V. Life-threatening ventricular tachycardia due to liquorice-induced hypokalemia. J Intern Med. 1999;245:307–10.CrossRefPubMed Eriksson JW, Carlberg B, Hillorn V. Life-threatening ventricular tachycardia due to liquorice-induced hypokalemia. J Intern Med. 1999;245:307–10.CrossRefPubMed
8.
go back to reference Gerritsen KGF, Meulenbelt J, Spiering W, Kema IP, Demir A, van Driel VJHM. An unusual cause of ventricular fibrillation. Lancet 2009;373:1144. Gerritsen KGF, Meulenbelt J, Spiering W, Kema IP, Demir A, van Driel VJHM. An unusual cause of ventricular fibrillation. Lancet 2009;373:1144.
9.
go back to reference Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991;8:1831–51. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991;8:1831–51.
10.
go back to reference Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58:32–45.CrossRefPubMed Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58:32–45.CrossRefPubMed
11.
go back to reference Hayakawa H, Fukushima Y, Kato H, Fukumoto H, Kadota T, Yamamoto H, et al. Metabolism and disposition of novel des-fluoro quinolone garenoxacin in experimental animals and an interspecies scaling of pharmacokinetic parameters. DMD. 2003;31:1409–18. Hayakawa H, Fukushima Y, Kato H, Fukumoto H, Kadota T, Yamamoto H, et al. Metabolism and disposition of novel des-fluoro quinolone garenoxacin in experimental animals and an interspecies scaling of pharmacokinetic parameters. DMD. 2003;31:1409–18.
12.
go back to reference Gajjar DA, Bello A, Ge Z, Christopher L, Grasela DM. Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob Agents Chemother. 2003;47:2256–63.CrossRefPubMed Gajjar DA, Bello A, Ge Z, Christopher L, Grasela DM. Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob Agents Chemother. 2003;47:2256–63.CrossRefPubMed
Metadata
Title
Torsades de Pointes induced by a combination of garenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice
Authors
Kanyu Miyamoto
Hirohisa Kawai
Ryuhei Aoyama
Hitoshi Watanabe
Keisuke Suzuki
Norihiro Suga
Wataru Kitagawa
Naoto Miura
Kazuhiro Nishikawa
Hirokazu Imai
Publication date
01-04-2010
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 2/2010
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-009-0244-9

Other articles of this Issue 2/2010

Clinical and Experimental Nephrology 2/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.